Longevity Science — 2026-06-12

Top Research Findings

Life Biosciences Begins Human Testing of ER-100, a Cellular Rejuvenation Therapy

Life Biosciences has dosed the first human patient with ER-100, a cellular reprogramming therapy designed to reverse age-related vision loss and cellular aging. The FDA approved this novel therapy for human clinical trials, marking a major milestone in translating rejuvenation science from lab to clinic. This represents the first-ever reverse-aging treatment to enter human testing at scale.

Rapamycin Extends Lifespan Comparable to Caloric Restriction, Yet Limited Benefits for Healthy Adults

New research shows rapamycin extends lifespan approximately as much as dietary restriction in preclinical models, with no consistent sex-specific differences in response. However, recent evidence syntheses indicate rapamycin shows limited evidence for extending lifespan in healthy humans—benefits appear restricted to disease states and immunosuppression contexts. The drug remains a focus of longevity research but requires careful risk-benefit assessment for preventive use.

PEARL Trial: Rapamycin Improves Muscle and Bone Health in Older Adults

The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial—the first long-term clinical trial of rapamycin in humans—demonstrated that rapamycin supplementation improves muscle and bone health in older adults, providing evidence for musculoskeletal benefits distinct from lifespan extension claims.

Clinical Trials & Intervention Updates

PEARL Trial (NCT04488601): Positive Musculoskeletal Outcomes

The PEARL trial established rapamycin's safety and efficacy for improving bone density and muscle mass in older adults—outcomes critical for healthspan. This Phase 2/3 trial marks the most rigorous long-term human evidence for rapamycin's anti-aging effects to date, though effect sizes remain modest.

MILES Trial (NCT02432287): Metformin and Longevity

The Metformin in Longevity Study (MILES) continues enrollment, examining whether metformin—a diabetes drug with suggestive lifespan-extension data in animal models—can improve healthspan in non-diabetic older adults. Results remain pending.

Industry & Biotech Watch

NewLimit Raises $435M Series C at $3.1B Valuation, Eyes Clinical Opening in 2027

Brian Armstrong's longevity startup NewLimit closed a $435 million Series C round at a $3.1 billion post-money valuation, signaling strong investor confidence in cellular reprogramming approaches. The company plans to open its first clinical facility in 2027, accelerating the path from research to patient treatment.

Forbes: "The New Billionaire Bet Isn't AI — It's Longevity Biotech"

A new wave of mega-cap investment is flowing into longevity startups as AI-driven biology accelerates drug discovery and cellular engineering. Major funders include Jeff Bezos (Altos Labs, $3B), Sam Altman (Retro Biosciences, recently valued at $1.8B), and Peter Thiel's Methuselah Foundation, reshaping Silicon Valley's innovation portfolio.

Deep Dive: Intervention Evidence Check — Rapamycin in Healthy Adults

Current State of Evidence

Rapamycin is a macrolide antibiotic and mTOR inhibitor discovered in soil samples from Easter Island (Rapanui) in the 1970s. It is well-established as an immunosuppressant and anti-cancer agent. Animal studies consistently show lifespan extension—sometimes exceeding 25% in mice—making it one of the most reproducible pharmacological interventions in aging research.

Human Data: Limited and Mixed

The PEARL trial (2024) provided the first robust long-term human data, showing significant improvements in bone density and muscle mass—metrics that proxy for functional health. However, rapamycin did not demonstrate lifespan extension in this trial, which enrolled older adults with age-related decline. A separate 2025 analysis published in Aging-US concluded that rapamycin shows limited evidence for longevity benefits in healthy adults—the primary population interested in preventive anti-aging therapy.

What's Still Speculative

• Whether low-dose chronic rapamycin extends human lifespan (no data; ongoing trials needed)
• Optimal dosing and frequency for healthy individuals (immunosuppression risk is dose-dependent)
• Sex-specific responses (animal data show similar benefits across sexes; human confirmation pending)

What Readers Should Know Before Trying It

Rapamycin carries real risks: immunosuppression, increased infection risk, metabolic side effects, and potential increased cancer risk at higher doses. It is not approved for preventive use in healthy people and requires medical supervision. The evidence base supports its use in transplant recipients and cancer patients, but healthy individuals considering rapamycin for longevity should understand they are participating in an off-label experiment with uncertain benefit-to-risk ratio. The PEARL trial's positive musculoskeletal findings justify further research in older adults with frailty, but do not yet justify routine preventive use.

What to Watch Next

• Life Biosciences Phase 1 Data (expected late 2026–early 2027): First safety and efficacy readout from ER-100 human trial—critical validation of cellular reprogramming in humans.
• NewLimit Clinical Facility Opening (2027): First dedicated longevity clinic combining cellular rejuvenation with traditional medicine; will likely become a model for future treatment centers.
• Retro Biosciences and Altos Labs Pipeline Updates: Both companies are advancing cellular reprogramming programs toward IND-enabling studies; announcements expected in H2 2026.
• MILES Trial Results: Metformin efficacy data may reshape understanding of repurposed drugs for healthspan extension.

Reader Action Items

1. Track the ER-100 trial: If you or a family member struggles with age-related vision loss, monitor Life Biosciences' trial enrollment (clinicaltrials.gov, NCT# pending) for potential participation opportunities in coming months.

2. Rapamycin caution: Do not pursue off-label rapamycin for anti-aging without consulting a longevity-focused physician who can assess your individual risk profile. Current human evidence supports musculoskeletal health in older adults with decline, not preventive lifespan extension in healthy individuals.

3. Read the latest reviews: A comprehensive 2025 ScienceDirect review of repurposed drugs (aspirin, metformin, statins, GLP-1 agonists) for aging is freely available—excellent resource for understanding which interventions have human data vs. speculation.